Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Research & Development (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Research & Development for 4 consecutive years, with $40.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 33.77% to $40.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $148.1 million, a 34.94% decrease, with the full-year FY2025 number at $148.1 million, down 34.94% from a year prior.
  • Research & Development was $40.9 million for Q4 2025 at Day One Biopharmaceuticals, up from $31.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $92.1 million in Q2 2024 to a low of $15.0 million in Q1 2022.
  • A 4-year average of $37.0 million and a median of $33.4 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 186.2% in 2024, then crashed 60.75% in 2025.
  • Day One Biopharmaceuticals' Research & Development stood at $26.0 million in 2022, then soared by 43.54% to $37.3 million in 2023, then skyrocketed by 65.53% to $61.8 million in 2024, then tumbled by 33.77% to $40.9 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Research & Development are $40.9 million (Q4 2025), $31.4 million (Q3 2025), and $36.1 million (Q2 2025).